Results 41 to 50 of about 459,966 (302)

Multiple sclerosis [PDF]

Mental Health Clinician, 2019
Abstract Multiple sclerosis is a chronic, unpredictable, and disabling disease. Significant advances have been made in recent years supporting an earlier, more accurate, diagnosis and have led to more than 15 disease-modifying therapies approved by the Food and Drug Administration for relapsing forms of multiple sclerosis.
Shilpa Klocke, Nicole Hahn
openaire   +2 more sources

A meta-analysis of genomic screens in multiple sclerosis [PDF]

, 2001
We combined the raw genotyping data from three large multiple sclerosis genome screens and performed a global meta-analysis in order to compare and summarize the linkage results from the different studies. In alphabetical order, the screens provided data
Cooperative, The Transatlantic Multiple Sclerosis Genetics
core   +1 more source

Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models

NeuroImage: Clinical, 2015
Magnetic resonance imaging (MRI) of the brain provides important outcome measures in the longitudinal evaluation of disease activity and progression in MS subjects. Two common measures derived from brain MRI scans are the brain parenchymal fraction (BPF)
Alicia S. Chua, MS, Svetlana Egorova, MD, PhD, Mark C. Anderson, MS, Mariann Polgar-Turcsanyi, MS, Tanuja Chitnis, MD, Howard L. Weiner, MD, Charles R.G. Guttmann, MD, Rohit Bakshi, MD, Brian C. Healy, PhD   +8 more
doaj   +1 more source

Reduction in circulating vitamin D binding protein in patients with multiple sclerosis

BMC Neurology, 2021
Background In this study, we aimed to determine the risk association between vitamin D binding protein (VDBP) polymorphism in patients with multiple sclerosis (MS) in a MS biobank and the difference in VDBP serum levels in MS patients who were recently ...
Zhila Maghbooli, Abolfazl Omidifar, Tarlan Varzandi, Tayebeh Salehnezhad, Mohammad Ali Sahraian   +4 more
doaj   +1 more source

T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis [PDF]

, 2010
Objectives: Prediction of long term clinical outcome in patients with primary progressive multiple sclerosis (PPMS) using imaging has important clinical implications, but remains challenging.
Polman, C., Barkhof, F., Montalban, X, CHARD D, Thompson, A, Polman, C, F. Barkhof, Chard, D, Samson, R., D. Miller, Bodini, B., A. Thompson, Samson, R, MONTALBAN X, R. Samson, Rovira, A, POLMAN C, KHALEELI Z, O. Ciccarelli, Filippi, M., N. De Stefano, Barkhof, F, BATTAGLINI, MARCO, B. Bodini, A. Rovira, Battaglini, M, Polman, C.H., Chard, D., CICCARELLI O., Miller, D., Rovaris, M, Battaglini, M., Thompson, A., De Stefano, N., X. Montalban, MILLER D, ROVARIS M, FILIPPI M, D. Chard, Khaleeli, Z, SAMSON R, ROVIRA A, THOMPSON A, Rovaris, M., De Stefano, N, Rovira, A., Z. Khaleeli, Bodini, B, BODINI B, M. Filippi, Miller, D, BARKHOF F, DE STEFANO, NICOLA, M. Rovaris, Montalban, X., Ciccarelli, O., Ciccarelli, O, Khaleeli, Z., M. Battaglini, C. Polman, Filippi, M   +60 more
core   +1 more source

Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination [PDF]

, 2023
Background:People with multiple sclerosis (pwMS) treated with certain disease-modifying therapies (DMTs) have attenuated IgG response following COVID-19 vaccination; however, the clinical consequences remain unclear.Objective:To report COVID-19 rates in ...
Hibbert, A, Katharine E Harding, Samantha Loveless, Tank, Pooja, Matthew Upcott, Upcott, M, Schmierer, K, Robertson, NP, Richards, A, Dobson, R, Richards, Aidan, Zaloum, Safiya, Valerie Anderson, David Baker, Vickaryous, N, Baker, David, Wood, Callum, Tallantyre, Emma, Anderson, Valerie, Pooja Tank, Dobson, Ruth, Zaloum, Safiya A, Loveless, Samantha, Schmierer, Klaus, Callum H Wood, Harding, Katherine, Zaloum, SA, Katila George, Aimee Hibbert, Ruth Dobson, Kang, Angray S, George, Katila, Hibbert, Aimee, Moat, Stuart J., Stephen Jolles, Angray S Kang, Emma C Tallantyre, Robertson, Neil P., Baker, D, Jolles, Stephen, Ingram, Gillian, Willis, Mark, Stuart J Moat, Harding, Katharine E, Willis, M, Kang, Angray, Gillian Ingram, Harding, KE, Tallantyre, Emma C, Tank, P, Mark Willis, Gavin Giovannoni, Moat, Stuart J, Moat, SJ, Rios, F, Rios, Francesca, Ingram, G, Randy, Chance, Evangelou, Nikos, Chance, Randy, Neil P Robertson, Nicola Vickaryous, Tallantyre, EC, Robertson, Neil P, Safiya A Zaloum, Wood, Callum H, Randy Chance, Upcott, Matthew, Aidan Richards, Anderson, V, Klaus Schmierer, Loveless, S, Giovannoni, Gavin, Evangelou, N, Jolles, S, Vickaryous, Nicola, Nikos Evangelou, Chance, R, Kang, AS, Giovannoni, G, Francesca Rios, Wood, CH, George, K   +82 more
core   +2 more sources

Rational Use of Herbal Products in Pediatric Patients Treated With Anticancer Drugs in the European Union

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction The use of herbal medical preparation (HMP) is rising among pediatric oncology patients, often to manage treatment‐related symptoms. Their effectiveness remains uncertain, and the risk of herb–drug interactions is underestimated.
Orianne Mahot, Mathieu Corvaisier, Laurence Spiesser‐Robelet, Mylène Duplan, Isabelle Pellier, Delphine Bourneau‐Martin, Séverine Derbré   +6 more
wiley   +1 more source

Migration and infectious disease in the etiology of multiple sclerosis: A case-control study [PDF]

, 1989
Epidemiological study on multiple sclerosis risk of migration from South to North ...
Altobelli A., Italian Multiple Sclerosis Study Group, GRANIERI, Enrico Gavino Giuseppe   +2 more
core  

Survival by Race and Ethnicity in Children and Adolescents/Young Adults With Relapsed/Refractory Hodgkin Lymphoma: A Pooled Analysis of Children's Oncology Group Trials

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Despite 5‐year survival rates of over 90% among children and adolescents/young adults (CAYAs) with classic Hodgkin lymphoma (cHL), 15%–20% relapse after frontline therapy. Prior analysis of frontline Children's Oncology Group (COG) clinical trials demonstrated that, despite similar rates of relapse, non‐Hispanic Black (NHB) and ...
Mallorie B. Heneghan, Lindsay A. Renfro, Yue Wu, Katia M. Crisler, Erin Marcotte, Tanya Trippett, Terzah Horton, Bradford S. Hoppe, Frank G. Keller, Chris Forlenza, Cindy Schwartz, Kara M. Kelly, Peter D. Cole, Sharon M. Castellino, Justine M. Kahn   +14 more
wiley   +1 more source

The possible role of Interleukin-6 as a regulator of insulin sensitivity in patients with neuromyelitis optica spectrum disorder

BMC Neurology, 2021
Background Neuromyelitis optica spectrum disorder (NMOSD) is associated with inflammatory mediators that may also trigger downstream signaling pathways leading to reduce insulin sensitivity.
Zhila Maghbooli, Abdorreza Naser Moghadasi, Nasim Rezaeimanesh, Abolfazl Omidifar, Tarlan Varzandi, Mohammad Ali Sahraian   +5 more
doaj   +1 more source